[
    [
        {
            "time": "",
            "original_text": "【浙商医药|点评】从分众传媒到药明康德，CXO 的景气破了么?",
            "features": {
                "keywords": [
                    "浙商医药",
                    "点评",
                    "分众传媒",
                    "药明康德",
                    "CXO",
                    "景气"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【浙商医药|点评】从分众传媒到药明康德，CXO 的景气破了么?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]